Oligodendrocyte-protection and remyelination post-spinal cord injuries: A review

Progress in Neurobiology

Volumn 96, Issue 3, 2012, Pages 322-339

  Mekhail, Mina ^a   Almazan, Guillermina ^a   Tabrizian, Maryam ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Biomaterials; Drug delivery systems; Molecular therapies; Oligodendrocyte; Remyelination; Spinal cord injuries

Indexed keywords

ATORVASTATIN; GLUTAMIC ACID; GUANOSINE; LEUKEMIA INHIBITORY FACTOR; METHYLPREDNISOLONE; MINOCYCLINE; MYELIN; PROTEIN P75; ROLIPRAM; SELENIUM; SODIUM ION; STAT5 PROTEIN; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; APOPTOSIS; CELL DIFFERENTIATION; CELL MIGRATION; DRUG DELIVERY SYSTEM; HUMAN; MOLECULAR THERAPY; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OLIGODENDROCYTE PRECURSOR CELL; OLIGODENDROGLIA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REMYELINIZATION; REVIEW; SPINAL CORD INJURY; STEM CELL;

ANIMALS; DEMYELINATING DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; NERVE FIBERS, MYELINATED; NERVE GROWTH FACTORS; NERVE REGENERATION; NEUROPROTECTIVE AGENTS; OLIGODENDROGLIA; SPINAL CORD INJURIES; STEM CELLS;

EID: 84858325070     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2012.01.008     Document Type: Review

References (219)

1. Adams M., Cavanagh J.F.R. International Campaign for Cures of Spinal Cord Injury Paralysis (ICCP): another step forward for spinal cord injury research. Spinal Cord 2004, 42:273-280.
2. Agudo M., Woodhoo A., Webber D., Mirsky R., Jessen K.R., McMahon S.B. Schwann cell precursors transplanted into the injured spinal cord multiply, integrate and are permissive for axon growth. Glia 2008, 56:1263-1270.
3. Aktas Y., Andrieux K., Alonso M.J., Calvo P., Gursoy R.N., Couvreur P., Capan Y. Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor. Int. J. Pharm. 2005, 298:378-383.
4. Aktas Y., Yemisci M., Andrieux K., Gursoy R.N., Alonso M.J., Fernandez-Megia E., Novoa-Carballal R., Quinoa E., Riguera R., Sargon M.F., Celik H.H., Demir A.S., Hincal A.A., Dalkara T., Capan Y., Couvreur P. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug. Chem. 2005, 16:1503-1511.
5. Alberts A.W. Discovery, biochemistry and biology of lovastatin. Am. J. Cardiol. 1988, 62:10-15.
6. Althaus H.H., Kloppner S., Klopfleisch S., Schmitz M. Oligodendroglial cells and neurotrophins: a polyphonic cantata in major and minor. J. Mol. Neurosci. 2008, 35:65-79.
7. Asakura K., Miller D.J., Pease L.R., Rodriguez M. Targeting of IgMkappa antibodies to oligodendrocytes promotes CNS remyelination. J. Neurosci. 1998, 18:7700-7708.
8. Augst A.D., Kong H.J., Mooney D.J. Alginate hydrogels as biomaterials. Macromol. Biosci. 2006, 6:623-633.
9. Azari M.F., Profyris C., Karnezis T., Bernard C.C., Small D.H., Cheema S.S., Ozturk E., Hatzinisiriou I., Petratos S. Leukemia inhibitory factor arrests oligodendrocyte death and demyelination in spinal cord injury. J. Neuropathol. Exp. Neurol. 2006, 65:914-929.
10. Barres B.A., Raff M.C., Gaese F., Bartke I., Dechant G., Barde Y.A. A crucial role for neurotrophin-3 in oligodendrocyte development. Nature 1994, 367:371-375.
11. Baumann N., Pham-Dinh D. Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol. Rev. 2001, 81:871-927.
12. Beattie M.S., Harrington A.W., Lee R., Kim J.Y., Boyce S.L., Longo F.M., Bresnahan J.C., Hempstead B.L., Yoon S.O. ProNGF induces p75-mediated death of oligodendrocytes following spinal cord injury. Neuron 2002, 36:375-386.
13. Beaumont E., Whitaker C.M., Burke D.A., Hetman M., Onifer S.M. Effects of rolipram on adult rat oligodendrocytes and functional recovery after contusive cervical spinal cord injury. Neuroscience 2009, 163:985-990.
14. Bieber A.J., Warrington A., Asakura K., Ciric B., Kaveri S.V., Pease L.R., Rodriguez M. Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice. Glia 2002, 37:241-249.
15. Black J.A., Felts P., Smith K.J., Kocsis J.D., Waxman S.G. Distribution of sodium channels in chronically demyelinated spinal cord axons: immuno-ultrastructural localization and electrophysiological observations. Brain Res. 1991, 544:59-70.
16. Blakemor W.f. Remyelination of superior cerebellar peduncle in mouse following demyelination induced by feeding cuprizone. J. Neurolog. Sci. 1973, 20:73-83.
17. Blight A.R. Cellular morphology of chronic spinal-cord injury in the cat-analysis of myelinated axons by line-sampling. Neuroscience 1983, 10:521-543.
18. Blight A.R. Delayed demyelination and macrophage invasion: a candidate for secondary cell damage in spinal cord injury. Cent. Nerv. Syst. Trauma 1985, 2:299-315.
19. Blight A.R., Young W. Central axons in injured cat spinal cord recover electrophysiological function following remyelination by Schwann cells. J. Neurolog. Sci. 1989, 91:15-34.
20. Bostock H., Sears T.A. Continuous conduction in demyelinated mammalian nerve-fibers. Nature 1976, 263:786-787.
21. Boyd J.G., Doucette R., Kawaja M.D. Defining the role of olfactory ensheathing cells in facilitating axon remyelination following damage to the spinal cord. FASEB J. 2005, 19:694-703.
22. Bracken M.B., Collins W.F., Freeman D.F., Shepard M.J., Wagner F.W., Silten R.M., Hellenbrand K.G., Ransohoff J., Hunt W.E., Perot P.L., Grossman R.G., Green B.A., Eisenberg H.M., Rifkinson N., Goodman J.H., Meagher J.N., Fischer B., Clifton G.L., Flamm E.S., Rawe S.E. Efficacy of methylprednisolone in acute spinal cord injury. JAMA 1984, 251:45-52.
23. Bracken M.B., Shepard M.J., Collins W.F., Holford T.R., Young W., Baskin D.S., Eisenberg H.M., Flamm E., Leo-Summers L., Maroon J., et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N. Engl. J. Med. 1990, 322:1405-1411.
24. Bracken M.B., Shepard M.J., Collins W.F., Holford T.R., Young W., Baskin D.S., Eisenberg H.M., Flamm E., Leo-Summers L., Maroon J., Marshall L.F., Perot J.P.L., Piepmeier J., Sonntag V.K.H., Wagner F.C., Wilberger J.E., Winn H.R. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N. Engl. J. Med. 1990, 322:1405-1411.
25. Bracken M.B., Shepard M.J., Holford T.R., Leo-Summers L., Aldrich E.F., Fazl M., Fehlings M., Herr D.L., Hitchon P.W., Marshall L.F., Nockels R.P., Pascale V., Perot P.L., Piepmeier J., Sonntag V.K., Wagner F., Wilberger J.E., Winn H.R., Young W. Administration of methylprednisolone for 24 or 48h or tirilazad mesylate for 48h in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997, 277:1597-1604.
26. Bracken M.B., Shepard M.J., Holford T.R., Leo-Summers L., Aldrich E.F., Fazl M., Fehlings M.G., Herr D.L., Hitchon P.W., Marshall L.F., Nockels R.P., Pascale V., Perot P.L., Piepmeier J., Sonntag V.K., Wagner F., Wilberger J.E., Winn H.R., Young W. Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury randomized controlled trial. J. Neurosurg. 1998, 89:699-706.
27. Bunge R.P., Puckett W.R., Becerra J.L., Marcillo A., Quencer R.M. Observations on the pathology of human spinal cord injury. A review and classification of 22 new cases with details from a case of chronic cord compression with extensive focal demyelination. Adv. Neurol. 1993, 59:75-89.
28. Burdick J.A., Ward M., Liang E., Young M.J., Langer R. Stimulation of neurite outgrowth by neurotrophins delivered from degradable hydrogels. Biomaterials 2006, 27:452-459.
29. Butzkueven H., Zhang J.G., Hanninen M.S., Hochrein H., Chionh F., Shipham K.A., Emery B., Turnley A.M., Petratos S., Ernst M., Bartlett P.F., Kilpatrick T.J. LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nat. Med. 2002, 8:613-619.
30. Cai J., Ziemba K.S., Smith G.M., Jin Y. Evaluation of cellular organization and axonal regeneration through linear PLA foam implants in acute and chronic spinal cord injury. J. Biomed. Mater. Res. Part A 2007, 83A:512-520.
31. Cao Q., Xu X.M., Devries W.H., Enzmann G.U., Ping P., Tsoulfas P., Wood P.M., Bunge M.B., Whittemore S.R. Functional recovery in traumatic spinal cord injury after transplantation of multineurotrophin-expressing glial-restricted precursor cells. J. Neurosci. 2005, 25:6947-6957.
32. Carty M.L., Wixey J.A., Colditz P.B., Buller K.M. Post-insult minocycline treatment attenuates hypoxia-ischemia-induced neuroinflammation and white matter injury in the neonatal rat: a comparison of two different dose regimens. Int. J. Dev. Neurosci. 2008, 26:477-485.
33. Casha S., Yu W.R., Fehlings M.G. Oligodendroglial apoptosis occurs along degenerating axons and is associated with FAS and p75 expression following spinal cord injury in the rat. Neuroscience 2001, 103:203-218.
34. Casha S., Zygun D., McGowan D., Yong V.W., Hurlbert R.J. Neuroprotection with minocycline after spinal cord injury: results of a double blind, randomized, controlled pilot study. Neurosurgery 2009, 65:410-411.
35. Chen R.W., Williams A.J., Liao Z.L., Yao C.P., Tortella F.C., Dave J.R. Broad spectrum neuroprotection profile of phosphodiesterase inhibitors as related to modulation of cell-cycle elements and caspase-3 activation. Neurosci. Lett. 2007, 418:165-169.
36. Chen S.W., Xie Y.F. Glial implications in transplantation therapy of spinal cord injury. Chin. J. Traumatol. 2009, 12:55-61.
37. Chi G.F., Kim M., Kim D.W., Jiang M.H., Son Y. Schwann cells differentiated from spheroid-forming cells of rat subcutaneous fat tissue myelinate axons in the spinal cord injury. Exp. Neurol. 2010, 222:304-317.
38. Chowdhury I., Tharakan B., Bhat G.K. Caspases-An update. Comp. Biochem. Physiol. B-Biochem. Mol. Biol. 2008, 151:10-27.
39. Chvatal S.A., Kim Y.T., Bratt-Leal A.M., Lee H., Bellamkonda R.V. Spatial distribution and acute anti-inflammatory effects of Methylprednisolone after sustained local delivery to the contused spinal cord. Biomaterials 2008, 29:1967-1975.
40. Cohen-Adad J., El Mendili M.M., Lehericy S., Pradat P.F., Blancho S., Rossignol S., Benali H. Demyelination and degeneration in the injured human spinal cord detected with diffusion and magnetization transfer MRI. Neuroimage 2011, 55:1024-1033.
41. Craighead M.W., Tiwari P., Keynes R.G., Waters C.M. Human oligodendroglial cell line, MO3.13, can be protected from apoptosis using the general caspase inhibitor zVAD-FMK. J. Neurosci. Res. 1999, 57:236-243.
42. Crowe M.J., Bresnahan J.C., Shuman S.L., Masters J.N., Beattie M.S. Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat. Med. 1997, 3:73-76.
43. Cudrici C., Niculescu F., Jensen T., Zafranskaia E., Fosbrink M., Rus V., Shin M.L., Rus H. C5b-9 terminal complex protects oligodendrocytes from apoptotic cell death by inhibiting caspase-8 processing and up-regulating FLIP. J. Immunol. 2006, 176:3173-3180.
44. David S., Lacroix S. Molecular approaches to spinal cord repair. Annu. Rev. Neurosci. 2003, 26:411-440.
45. Dawson M.R., Polito A., Levine J.M., Reynolds R. NG2-expressing glial progenitor cells: an abundant and widespread population of cycling cells in the adult rat CNS. Mol. Cell. Neurosci. 2003, 24:476-488.
46. De Nicola A.F., Gonzalez S.L., Labombarda F., Deniselle M.C., Garay L., Guennoun R., Schumacher M. Progesterone treatment of spinal cord injury: Effects on receptors, neurotrophins, and myelination. J. Mol. Neurosci. 2006, 28:3-15.
47. De Nicola A.F., Labombarda F., Gonzalez S.L., Gonzalez Deniselle M.C., Guennoun R., Schumacher M. Steroid effects on glial cells: detrimental or protective for spinal cord function?. Ann. N. Y. Acad. Sci. 2003, 1007:317-328.
48. Dery M.A., Rousseau G., Benderdour M., Beaumont E. Atorvastatin prevents early apoptosis after thoracic spinal cord contusion injury and promotes locomotion recovery. Neurosci. Lett. 2009, 453:73-76.
49. Dsouza S., Alinauskas K., Mccrea E., Goodyer C., Antel J.P. Differential susceptibility of human Cns-derived cell-populations to Tnf-dependent and independent immune-mediated injury. J. Neurosci. 1995, 15:7293-7300.
50. Ducker T.B., Hamit H.F. Experimental treatments of acute spinal cord injury. J. Neurosurg. 1969, 30:693-697.
51. Emery E., Aldana P., Bunge M.B., Puckett W., Srinivasan A., Keane R.W., Bethea J., Levi A.D. Apoptosis after traumatic human spinal cord injury. J. Neurosurg. 1998, 89:911-920.
52. England J.D., Gamboni F., Levinson S.R., Finger T.E. Changed distribution of sodium-channels along demyelinated axons. Proc. Natl. Acad. Sci. U.S.Am. 1990, 87:6777-6780.
53. Faulkner J., Keirstead H.S. Human embryonic stem cell-derived oligodendrocyte progenitors for the treatment of spinal cord injury. Transpl. Immunol. 2005, 15:131-142.
54. Felleiter P., Muller N., Schumann F., Felix O., Lierz P. Changes in the use of the methylprednisolone protocol for traumatic spinal cord injury in Switzerland. Spine 2011.
55. Felts P.A., Smith K.J. Conduction properties of central nerve fibers remyelinated by Schwann cells. Brain Res. 1992, 574:178-192.
56. Ffrench-Constant C., Raff M.C. Proliferating bipotential glial progenitor cells in adult rat optic nerve. Nature 1986, 319:499-502.
57. Fortun J., Hill C.E., Bunge M.B. Combinatorial strategies with Schwann cell transplantation to improve repair of the injured spinal cord. Neurosci. Lett. 2009, 456:124-132.
58. Franklin R.J., Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat. Rev. Neurosci. 2008, 9:839-855.
59. Franklin R.J.M., Blakemore W.F. Requirements for Schwann-cell migration within Cns environments-a viewpoint. Int. J. Dev. Neurosci. 1993, 11:641-649.
60. Frizzo M.E.D., Lara D.R., Prokopiuk A.D., Vargas C.R., Salbego C.G., Wajner M., Souza D.O. Guanosine enhances glutamate uptake in brain cortical slices at normal and excitotoxic conditions. Cell. Mol. Neurobiol. 2002, 22:353-363.
61. Frizzo M.E.S., Lara D.R., Dahm K.C.S., Prokopiuk A.S., Swanson R.A., Souza D.O. Activation of glutamate uptake by guanosine in primary astrocyte cultures. Neuroreport 2001, 12:879-881.
62. Garcia P.J. Pleiotropic effects of statins: moving beyond cholesterol control. Curr. Atheroscler Rep. 2005, 7:34-39.
63. Gard A.L., Burrell M.R., Pfeiffer S.E., Rudge J.S., Williams W.C. Astroglial control of oligodendrocyte survival mediated by Pdgf and leukemia inhibitory factor-like protein. Development 1995, 121:2187-2197.
64. Gensert J.M., Goldman J.E. Endogenous progenitors remyelinate demyelinated axons in the adult CNS. Neuron 1997, 19:197-203.
65. Gerndt S.J., Rodriguez J.L., Pawlik J.W., Taheri P.A., Wahl W.L., Micheals A.J., Papadopoulos S.M. Consequences of high-dose steroid therapy for acute spinal cord injury. J. Trauma 1997, 42:279-284.
66. Ghidoni I., Chlapanidas T., Bucco M., Crovato F., Marazzi M., Vigo D., Torre M.L., Faustini M. Alginate cell encapsulation: new advances in reproduction and cartilage regenerative medicine. Cytotechnology 2008, 58:49-56.
67. Girard C., Bemelmans A.P., Dufour N., Mallet J., Bachelin C., Nait-Oumesmar B., Baron-Van Evercooren A., Lachapelle F. Grafts of brain-derived neurotrophic factor and neurotrophin 3-transduced primate Schwann cells lead to functional recovery of the demyelinated mouse spinal cord. J. Neurosci. 2005, 25:7924-7933.
68. Gledhill R.F., Mcdonald W.I. Morphological-characteristics of central demyelination and remyelination - single-fiber study. Ann. Neurol. 1977, 1:552-560.
69. Griffiths I.R., Mcculloch M.C. Nerve-fibers in spinal-cord impact injuries 1. Changes in the myelin sheath during the initial 5 weeks. J. Neurol. Sci. 1983, 58:335-349.
70. Groves A.K., Barnett S.C., Franklin R.J., Crang A.J., Mayer M., Blakemore W.F., Noble M. Repair of demyelinated lesions by transplantation of purified O-2A progenitor cells. Nature 1993, 362:453-455.
71. Gu J., Royland J.E., Wiggins R.C., Konat G.W. Selenium is required for normal upregulation of myelin genes in differentiating oligodendrocytes. J. Neurosci. Res. 1997, 47:626-635.
72. Guest J.D., Hiester E.D., Bunge R.P. Demyelination and Schwann cell responses adjacent to injury epicenter cavities following chronic human spinal cord injury. Exp. Neurol. 2005, 192:384-393.
73. Guimaraes J.S., Freire M.A.M., Lima R.R., Picanco-Diniz C.W., Pereira A., Gomes-Leal W. Minocycline treatment reduces white matter damage after excitotoxic striatal injury. Brain Res. 2010, 1329:182-193.
74. Gupta D., Tator C.H., Shoichet M.S. Fast-gelling injectable blend of hyaluronan and methylcellulose for intrathecal, localized delivery to the injured spinal cord. Biomaterials 2006, 27:2370-2379.
75. Hall E.D. Antioxidant therapies for acute spinal cord injury. Neurotherapeutics 2011, 8:152-167.
76. Hall E.D., Braughler J.M. Glucocorticoid mechanisms in acute spinal cord injury: a review and therapeutic rationale. Surg. Neurol. 1982, 18:320-327.
77. Hall E.D., Springer J.E. Neuroprotection and acute spinal cord injury: a reappraisal. NeuroRx 2004, 1:80-100.
78. Harrison B.M., Mcdonald W.I. Remyelination after transient experimental compression of spinal-cord. Ann. Neurol. 1977, 1:542-551.
79. Hohlfeid R., Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:14599-14606.
80. Horner P.J., Gage F.H. Regenerating the damaged central nervous system. Nature 2000, 407:963-970.
81. Iannotti C., Li H., Yan P., Lu X., Wirthlin L., Xu X.M. Glial cell line-derived neurotrophic factor-enriched bridging transplants promote propriospinal axonal regeneration and enhance myelination after spinal cord injury. Exp. Neurol. 2003, 183:379-393.
82. Ibanez C., Shields S.A., El-Etr M., Baulieu E.E., Schumacher M., Franklin R.J. Systemic progesterone administration results in a partial reversal of the age-associated decline in CNS remyelination following toxin-induced demyelination in male rats. Neuropathol. Appl. Neurobiol. 2004, 30:80-89.
83. Imai M., Watanabe M., Suyama K., Osada T., Sakai D., Kawada H., Matsumae M., Mochida J. Delayed accumulation of activated macrophages and inhibition of remyelination after spinal cord injury in an adult rodent model. J. Neurosurg. Spine 2008, 8:58-66.
84. Ishii K., Toda M., Nakai Y., Asou H., Watanabe M., Nakamura M., Yato Y., Fujimura Y., Kawakami Y., Toyama Y., Uyemura K. Increase of oligodendrocyte progenitor cells after spinal cord injury. J. Neurosci. Res. 2001, 65:500-507.
85. Jain A., Kim Y.T., McKeon R.J., Bellamkonda R.V. In situ gelling hydrogels for conformal repair of spinal cord defects, and local delivery of BDNF after spinal cord injury. Biomaterials 2006, 27:497-504.
86. Jayakumar R., Menon D., Manzoor K., Nair S.V., Tamura H. Biomedical applications of chitin and chitosan based nanomaterials-a short review. Carbohydrate Polym. 2010, 82:227-232.
87. Jiang S., Bendjelloul F., Ballerini P., D'Alimonte I., Nargi E., Jiang C., Huang X., Rathbone M.P. Guanosine reduces apoptosis and inflammation associated with restoration of function in rats with acute spinal cord injury. Purinergic Signal. 2007, 3:411-421.
88. Jiang S., Khan M.I., Lu Y., Wang J., Buttigieg J., Werstiuk E.S., Ciccarelli R., Caciagli F., Rathbone M.P. Guanosine promotes myelination and functional recovery in chronic spinal injury. Neuroreport 2003, 14:2463-2467.
89. Jiang S.C., Ballerini P., Buccella S., Giuliani P., Jiang C., Huang X.J., Rathbone M.P. Remyelination after chronic spinal cord injury is associated with proliferation of endogenous adult progenitor cells after systemic administration of guanosine. Purinergic Signall. 2008, 4:61-71.
90. Johnson J.R., Chu A.K., Sato-Bigbee C. Possible role of CREB in the stimulation of oligodendrocyte precursor cell proliferation by neurotrophin-3. J. Neurochem. 2000, 74:1409-1417.
91. Kahn M.A., Devellis J. Regulation of an oligodendrocyte progenitor-cell line by the interleukin-6 family of cytokines. Glia 1994, 12:87-98.
92. Kajana S., Goshgarian H.G. Systemic administration of rolipram increases medullary and spinal cAMP and activates a latent respiratory motor pathway after high cervical spinal cord injury. J. Spinal Cord Med. 2009, 32:175-182.
93. Kakulas B.A. A review of the neuropathology of human spinal cord injury with emphasis on special features. J. Spinal Cord Med. 1999, 22:119-124.
94. Karatas H., Aktas Y., Gursoy-Ozdemir Y., Bodur E., Yemisci M., Caban S., Vural A., Pinarbasli O., Capan Y., Fernandez-Megia E., Novoa-Carballal R., Riguera R., Andrieux K., Couvreur P., Dalkara T. A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. J. Neurosci. Off. J. Soc. Neurosci. 2009, 29:13761-13769.
95. Kataoka K., Suzuki Y., Kitada M., Ohnishi K., Suzuki K., Tanihara M., Ide C., Endo K., Nishimura Y. Alginate, a bioresorbable material derived from brown seaweed, enhances elongation of amputated axons of spinal cord in infant rats. J. Biomed. Mater. Res. 2001, 54:373-384.
96. Kavanaugh B., Beesley J., Itoh T., Itoh A., Grinspan J., Pleasure D. Neurotrophin-3 (NT-3) diminishes susceptibility of the oligodendroglial lineage to AMPA glutamate receptor-mediated excitotoxicity. J. Neurosci. Res. 2000, 60:725-732.
97. Keirstead H.S., Levine J.M., Blakemore W.F. Response of the oligodendrocyte progenitor cell population (defined by NG2 labelling) to demyelination of the adult spinal cord. Glia 1998, 22:161-170.
98. Keirstead H.S., Nistor G., Bernal G., Totoiu M., Cloutier F., Sharp K., Steward O. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J. Neurosci. Off. J. Soc. Neurosci. 2005, 25:4694-4705.
99. Kerr B.J., Patterson P.H. Leukemia inhibitory factor promotes oligodendrocyte survival after spinal cord injury. Glia 2005, 51:73-79.
100. Kigerl K.A., Gensel J.C., Ankeny D.P., Alexander J.K., Donnelly D.J., Popovich P.G. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J. Neurosci. 2009, 29:13435-13444.
101. Kim Y.T., Caldwell J.M., Bellamkonda R.V. Nanoparticle-mediated local delivery of Methylprednisolone after spinal cord injury. Biomaterials 2009, 30:2582-2590.
102. King V.R., Alovskaya A., Wei D.Y.T., Brown R.A., Priestley J.V. The use of injectable forms of fibrin and fibronectin to support axonal ingrowth after spinal cord injury. Biomaterials 2010, 31:4447-4456.
103. King V.R., Henseler M., Brown R.A., Priestley J.V. Mats made from fibronectin support oriented growth of axons in the damaged spinal cord of the adult rat. Exp. Neurol. 2003, 182:383-398.
104. King V.R., Hewazy D., Alovskaya A., Phillips J.B., Brown R.A., Priestley J.V. The neuroprotective effects of fibronectin mats and fibronectin peptides following spinal cord injury in the rat. Neuroscience 2010, 168:523-530.
105. King V.R., Phillips J.B., Hunt-Grubbe H., Brown R., Priestley J.V. Characterization of non-neuronal elements within fibronectin mats implanted into the damaged adult rat spinal cord. Biomaterials 2006, 27:485-496.
106. Klein N.C., Cunha B.A. Tetracyclines. Med. Clin. North Am. 1995, 79:789-801.
107. Kocsis J.D., Lankford K.L., Sasaki M., Radtke C. Unique in vivo properties of olfactory ensheathing cells that may contribute to neural repair and protection following spinal cord injury. Neurosci. Lett. 2009, 456:137-142.
108. Koopmans G.C., Deumens R., Buss A., Geoghegan L., Myint A.M., Honig W.H., Kern N., Joosten E.A., Noth J., Brook G.A. Acute rolipram/thalidomide treatment improves tissue sparing and locomotion after experimental spinal cord injury. Exp. Neurol. 2009.
109. Kwon B.K., Tetzlaff W., Grauer J.N., Beiner J., Vaccaro A.R. Pathophysiology and pharmacologic treatment of acute spinal cord injury. Spine J. 2004, 4:451-464.
110. Labombarda F., Gonzalez S.L., Deniselle M.C., Vinson G.P., Schumacher M., De Nicola A.F., Guennoun R. Effects of injury and progesterone treatment on progesterone receptor and progesterone binding protein 25-Dx expression in the rat spinal cord. J. Neurochem. 2003, 87:902-913.
111. Lasiene J., Shupe L., Perlmutter S., Horner P. No evidence for chronic demyelination in spared axons after spinal cord injury in a mouse. J. Neurosci. 2008, 28:3887-3896.
112. Lassmann H., Bruck W., Lucchinetti C.F. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007, 17:210-218.
113. Lavdas A.A., Papastefanaki F., Thomaidou D., Matsas R. Schwann cell transplantation for CNS repair. Curr. Med. Chem. 2008, 15:151-160.
114. Lee H.C., Cho D.Y., Lee W.Y., Chuang H.C. Pitfalls in treatment of acute cervical spinal cord injury using high-dose methylprednisolone: a retrospect audit of 111 patients. Surg. Neurol. 2007, 68:S37-S42.
115. Lee J.H., Tigchelaar S., Liu J., Stammers A.M., Streijger F., Tetzlaff W., Kwon B.K. Lack of neuroprotective effects of simvastatin and minocycline in a model of cervical spinal cord injury. Exp. Neurol. 2010, 225:219-230.
116. Lee J.M., Yan P., Xiao Q., Chen S., Lee K.Y., Hsu C.Y., Xu J. Methylprednisolone protects oligodendrocytes but not neurons after spinal cord injury. J. Neurosci. 2008, 28:3141-3149.
117. Lee R., Kermani P., Teng K.K., Hempstead B.L. Regulation of cell survival by secreted proneurotrophins. Science 2001, 294:1945-1948.
118. Leipzig N.D., Shoichet M.S. The effect of substrate stiffness on adult neural stem cell behavior. Biomaterials 2009, 30:6867-6878.
119. Li W.W., Setzu A., Zhao C., Franklin R.J.M. Minocycline-mediated inhibition of microglia activation impairs oligodendrocyte progenitor cell responses and remyelination in a non-immune model of demyelination. J. Neuroimmunol. 2005, 158:58-66.
120. Li X.G., Yang Z.Y., Zhang A.F., Wang T.L., Chen W.C. Repair of thoracic spinal cord injury by chitosan tube implantation in adult rats. Biomaterials 2009, 30:1121-1132.
121. Li Y., Raisman G. Integration of transplanted cultured Schwann cells into the long myelinated fiber tracts of the adult spinal cord. Exp. Neurol. 1997, 145:397-411.
122. Liao J.K., Laufs U. Pleiotropic effects of statins. Ann. Rev. Pharmacol. Toxicol. 2005, 45:89-118.
123. Liu X.Z., Xu X.M., Hu R., Du C., Zhang S.X., McDonald J.W., Dong H.X., Wu Y.J., Fan G.S., Jacquin M.F., Hsu C.Y., Choi D.W. Neuronal and glial apoptosis after traumatic spinal cord injury. J. Neurosci. 1997, 17:5395-5406.
124. Ludwin S.K., Maitland M. Long-term remyelination fails to reconstitute normal thickness of central myelin sheaths. J. Neurol. Sci. 1984, 64:193-198.
125. Lytle J.M., Chittajallu R., Wrathall J.R., Gallo V. NG2 cell response in the CNP-EGFP mouse after contusive spinal cord injury. Glia 2009, 57:270-285.
126. Mackay-Sim A., St John J.A. Olfactory ensheathing cells from the nose: clinical application in human spinal cord injuries. Exp. Neurol. 2011, 229:174-180.
127. Mayer M., Bhakoo K., Noble M. Ciliary neurotrophic factor and leukemia inhibitory factor promote the generation, maturation and survival of oligodendrocytes in vitro. Development 1994, 120:143-153.
128. McBride C.B., McPhail L.T., Vanderluit J.L., Tetzlaff W., Steeves J.D. Caspase inhibition attenuates transection-induced oligodendrocyte apoptosis in the developing chick spinal cord. Mol. Cell. Neurosci. 2003, 23:383-397.
129. McDonald J.W., Belegu V. Demyelination and remyelination after spinal cord injury. J. Neurotrauma 2006, 23:345-359.
130. Mcdonald W.I. Remyelination in relation to clinical lesions of central nervous-system. Br. Med. Bull. 1974, 30:186-189.
131. McTigue D.M., Horner P.J., Stokes B.T., Gage F.H. Neurotrophin-3 and brain-derived neurotrophic factor induce oligodendrocyte proliferation and myelination of regenerating axons in the contused adult rat spinal cord. J. Neurosci. 1998, 18:5354-5365.
132. McTigue D.M., Wei P., Stokes B.T. Proliferation of NG2-positive cells and altered oligodendrocyte numbers in the contused rat spinal cord. J. Neurosci. 2001, 21:3392-3400.
133. Merrill J.E., Ignarro L.J., Sherman M.P., Melinek J., Lane T.E. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric-oxide. J. Immunol. 1993, 151:2132-2141.
134. Mo L.H., Yang Z.Y., Zhang A.F., Li X.G. The repair of the injured adult rat hippocampus with NT-3-chitosan carriers. Biomaterials 2010, 31:2184-2192.
135. Molano M.D., Broton J.G., Bean J.A., Calancie B. Complications associated with the prophylactic use of methylprednisolone during surgical stabilization after spinal cord injury. J. Neurosurg. 2002, 96:267-272.
136. Moretto M.B., Arteni N.S., Lavinsky D., Netto C.A., Rocha J.B.T., Souza D.O., Wofchuk S. Hypoxic-ischemic insult decreases glutamate uptake by hippocampal slices from neonatal rats: Prevention by guanosine. Exp. Neurol. 2005, 195:400-406.
137. Muzzarelli R.A.A., Muzzarelli C. Chitosan chemistry: Relevance to the biomedical sciences. Polysaccharides 1: Struct. Charact. Use 2005, 186:151-209.
138. Noble M., Mayer-Proschel M., Davies J.E., Davies S.J., Proschel C. Cell therapies for the central nervous system: how do we identify the best candidates?. Curr. Opin. Neurol. 2011.
139. Nomura H., Baladie B., Katayama Y., Morshead C.M., Shoichet M.S., Tator C.H. Delayed implantation of intramedullary chitosan channels containing nerve grafts promotes extensive axonal regeneration after spinal cord injury. Neurosurgery 2008, 63:127-141.
140. Nomura H., Zahir T., Kim H., Katayama Y., Kulbatski I., Morshead C.M., Shoichet M.S., Tator C.H. Extramedullary chitosan channels promote survival of transplanted neural stem and progenitor cells and create a tissue bridge after complete spinal cord transection. Tissue Eng. Part A 2008, 14:649-665.
141. Norenberg M.D., Smith J., Marcillo A. The pathology of human spinal cord injury: defining the problems. J. Neurotrauma 2004, 21:429-440.
142. Nottingham S., Knapp P., Springer J. FK506 treatment inhibits caspase-3 activation and promotes oligodendroglial survival following traumatic spinal cord injury. Exp. Neurol. 2002, 177:242-251.
143. Onose G., Anghelescu A., Muresanu D.F., Padure L., Haras M.A., Chendreanu C.O., Onose L.V., Mirea A., Ciurea A.V., El Masri W.S., von Wild K.R. A review of published reports on neuroprotection in spinal cord injury. Spinal Cord 2009, 47:716-726.
144. Oudega M., Xu X.M. Schwann cell transplantation for repair of the adult spinal cord. J. Neurotrauma 2006, 23:453-467.
145. Pannu R., Barbosa E., Singh A.K., Singh I. Attenuation of acute inflammatory response by atorvastatin following spinal cord injury in rats. J. Neurochem. 2004, 90:69.
146. Park D.H., Lee J.H., Borlongan C.V., Sanberg P.R., Chung Y.G., Cho T.H. Transplantation of umbilical cord blood stem cells for treating spinal cord injury. Stem Cell Rev. 2011, 7:181-194.
147. Patist C.M., Mulder M.B., Gautier S.E., Maquet V., Jerome R., Oudega M. Freeze-dried poly(D,L-lactic acid) macroporous guidance scaffolds impregnated with brain-derived neurotrophic factor in the transected adult rat thoracic spinal cord. Biomaterials 2004, 25:1569-1582.
148. Pearse D.D., Pereira F.C., Marcillo A.E., Bates M.L., Berrocal Y.A., Filbin M.T., Bunge M.B. cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury. Nat. Med. 2004, 10:610-616.
149. Pearse D.D., Sanchez A.R., Pereira F.C., Andrade C.M., Puzis R., Pressman Y., Golden K., Kitay B.M., Blits B., Wood P.M., Bunge M.B. Transplantation of Schwann cells and/or olfactory ensheathing glia into the contused spinal cord: Survival, migration, axon association, and functional recovery. Glia 2007, 55:976-1000.
150. Peters A. Observations on connexions between myelin sheaths + glial cells in optic nerves of young rats. J. Anatomy 1964, 98:125-134.
151. Pettiford J.N., Bikhchandani J., Ostlie D.J., St Peter S.D., Sharp R.J., Juang D. A review: the role of high dose methylprednisolone in spinal cord trauma in children. Pediatr. Surg. Int. 2011.
152. Pinzon A., Marcillo A., Quintana A., Stamler S., Bunge M.B., Bramlett H.M., Dietrich W.D. A re-assessment of minocycline as a neuroprotective agent in a rat spinal cord contusion model. Brain Res. 2008, 1243:146-151.
153. Poliak S., Peles E. The local differentiation of myelinated axons at nodes of Ranvier. Nat. Rev. Neurosci. 2003, 4:968-980.
154. Popovich P.G., Jones T.B. Manipulating neuroinflammatory reactions in the injured spinal cord: back to basics. Trends Pharmacol. Sci. 2003, 24:13-17.
155. Prang P., Muller R., Eljaouhari A., Heckmann K., Kunz W., Weber T., Faber C., Vroemen M., Bogdahn U., Weidner N. The promotion of oriented axonal regrowth in the injured spinal cord by alginate-based anisotropic capillary hydrogels. Biomaterials 2006, 27:3560-3569.
156. Qian T., Guo X., Levi A.D., Vanni S., Shebert R.T., Sipski M.L. High-dose methylprednisolone may cause myopathy in acute spinal cord injury patients. Spinal Cord 2005, 43:199-203.
157. Qiao F., Atkinson C., Song H., Pannu R., Singh I., Tomlinson S. Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma. Am. J. Pathol. 2006, 169:1039-1047.
158. Qin Y.M. The gel swelling properties of alginate fibers and their applications in wound management. Polym. Adv. Technol. 2008, 19:6-14.
159. Ramon-Cueto A., Munoz-Quiles C. Clinical application of adult olfactory bulb ensheathing glia for nervous system repair. Exp. Neurol. 2011, 229:181-194.
160. Rathbone M.P., Middlemiss P.J., Gysbers J.W., Andrew C., Herman M.A., Reed J.K., Ciccarelli R., Di Iorio P., Caciagli F. Trophic effects of purines in neurons and glial cells. Prog. Neurobiol. 1999, 59:663-690.
161. Remahl S., Hildebrand C. Relation between axons and oligodendroglial cells during initial myelination. 1. The Glial Unit. J. Neurocytol. 1990, 19:313-328.
162. Rodriguez M., Lennon V.A. Immunoglobulins promote remyelination in the central nervous system. Ann. Neurol. 1990, 27:12-17.
163. Ruoslahti E. Fibronectin. J. Oral. Pathol. Med. 1981, 10:3-13.
164. Saganova K., Orendacova J., Cizkova D., Vanicky I. Limited minocycline neuroprotection after balloon-compression spinal cord injury in the rat. Neurosci. Lett. 2008, 433:246-249.
165. Saini H.S., Gorse K.M., Boxer L.M., Sato-Bigbee C. Neurotrophin-3 and a CREB-mediated signaling pathway regulate Bcl-2 expression in oligodendrocyte progenitor cells. J. Neurochem. 2004, 89:951-961.
166. Sayer F.T., Kronvall E., Nilsson O.G. Methylprednisolone treatment in acute spinal cord injury: the myth challenged through a structured analysis of published literature. Spine J. Off. J. North Am. Spine Soc. 2006, 6:335-343.
167. Schaal S.M., Pearse D.D. TNF-alpha production in oligodendrocytes after moderate cervical spinal cord injury. Exp. Neurol. 2006, 198. 587-587.
168. Schwab J.M., Brechtel K., Mueller C.A., Failli V., Kaps H.P., Tuli S.K., Schluesener H.J. Experimental strategies to promote spinal cord regeneration--an integrative perspective. Prog. Neurobiol. 2006, 78:91-116.
169. Sharma H.S. Neurotrophic factors in combination: a possible new therapeutic strategy to influence pathophysiology of spinal cord injury and repair mechanisms. Curr. Pharm. Des. 2007, 13:1841-1874.
170. Slaets H., Dumont D., Vanderlocht J., Noben J.P., Leprince P., Robben J., Hendriks J., Stinissen P., Hellings N. Leukemia inhibitory factor induces an antiapoptotic response in oligodendrocytes through Akt-phosphorylation and up-regulation of 14-3-3. Proteomics 2008, 8:1237-1247.
171. Soane L., Rus H., Niculescu F., Shin M.L. Inhibition of oligodendrocyte apoptosis by sublytic C5b-9 is associated with enhanced synthesis of Bcl-2 and mediated by inhibition of caspase-3 activation. J. Immunol. 1999, 163:6132-6138.
172. Souness J.E., Aldous D., Sargent C. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 2000, 47:127-162.
173. Springer J.E., Azbill R.D., Knapp P.E. Activation of the caspase-3 apoptotic cascade in traumatic spinal cord injury. Nat. Med. 1999, 5:943-946.
174. Stidworthy M.F., Genoud S., Suter U., Mantei N., Franklin R.J. Quantifying the early stages of remyelination following cuprizone-induced demyelination. Brain Pathol. 2003, 13:329-339.
175. Stirling D.P., Khodarahmi K., Liu J., McPhail L.T., McBride C.B., Steeves J.D., Ramer M.S., Tetzlaff W. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J. Neurosci. 2004, 24:2182-2190.
176. Stirling D.R., Koochesfahani K.M., Steeves J.D., Tetzlaff W. Minocycline as a neuroprotective agent. Neuroscientist 2005, 11:308-322.
177. Straley K.S., Foo C.W.P., Heilshorn S.C. Biomaterial design strategies for the treatment of spinal cord injuries. J. Neurotrauma 2010, 27:1-19.
178. Stuve O., Youssef S., Dunn S., Slavin A.J., Steinmann L., Zamvil S.S. The potential therapeutic role of statins in central nervous system autoimmune disorders. Cell. Mol. Life Sci. 2003, 60:2483-2491.
179. Suberviola B., Gonzalez-Castro A., Llorca J., Ortiz-Melon F., Minambres E. Early complications of high-dose methylprednisolone in acute spinal cord injury patients. Injury 2008, 39:748-752.
180. Suzuki K., Suzuki Y., Ohnishi K., Endo K., Tanihara M., Nishimura Y. Regeneration of transected spinal cord in young adult rats using freeze-dried alginate gel. Neuroreport 1999, 10:2891-2894.
181. Tabesh H., Amoabediny G., Nik N.S., Heydari M., Yosefifard M., Siadat S.O., Mottaghy K. The role of biodegradable engineered scaffolds seeded with Schwann cells for spinal cord regeneration. Neurochem. Int. 2009, 54:73-83.
182. Talbott J.F., Loy D.N., Liu Y., Qiu M.S., Bunge M.B., Rao M.S., Whittemore S.R. Endogenous Nkx2.2(+)/Olig2(+) oligodendrocyte precursor cells fail to remyelinate the demyelinated adult rat spinal cord in the absence of astrocytes. Exp. Neurol. 2005, 192:11-24.
183. Tator C.H. Update on the pathophysiology and pathology of acute spinal cord injury. Brain Pathol. 1995, 5:407-413.
184. Tator C.H. Biology of neurological recovery and functional restoration after spinal cord injury. Neurosurgery 1998, 42:696-707. discussion 707-698.
185. Taylor S.J., McDonald J.W., Sakiyama-Elbert S.E. Controlled release of neurotrophin-3 from fibrin gels for spinal cord injury. J. Control. Release 2004, 98:281-294.
186. Tetzlaff W., et al. A systematic review of cellular transplantation therapies for spinal cord injury. Journal of Neurotrauma 2011, 28(8):1611-1682.
187. Thein-Han W.W., Kitiyanant Y., Misra R.D.K. Chitosan as scaffold matrix for tissue engineering. Mater. Sci. Technol. 2008, 24:1062-1075.
188. Thuret S., Moon L.D., Gage F.H. Therapeutic interventions after spinal cord injury. Nat. Rev. Neurosci. 2006, 7:628-643.
189. Totoiu M.O., Keirstead H.S. Spinal cord injury is accompanied by chronic progressive demyelination. J. Comp. Neurol. 2005, 486:373-383.
190. Turnley A.M., Bartlett P.F. Cytokines that signal through the leukemia inhibitory factor receptor-beta complex in the nervous system. J. Neurochem. 2000, 74:889-899.
191. Vanevercooren A.B., Gansmuller A., Duhamel E., Pascal F., Gumpel M. Repair of a myelin lesion by schwann-cells transplanted in the adult-mouse spinal-cord. J. Neuroimmunol. 1992, 40:235-242.
192. Vartanian T., Li Y., Zhao M.J., Stefansson K. Interferon-gamma-induced oligodendrocyte cell-death - implications for the pathogenesis of multiple-sclerosis. Mol. Med. 1995, 1:732-743.
193. Vos J.P., Gard A.L., Pfeiffer S.E. Regulation of oligodendrocyte cell survival and differentiation by ciliary neurotrophic factor, leukemia inhibitory factor, oncostatin M, and interleukin-6. Perspect. Dev. Neurobiol. 1996, 4:39-52.
194. Wang G., Lu G., Ao Q., Gong Y., Zhang X. Preparation of cross-linked carboxymethyl chitosan for repairing sciatic nerve injury in rats. Biotechnol. Lett. 2009, 32:59-66.
195. Warrington A.E., Rodriguez M. Remyelination-promoting human IgMs: developing a therapeutic reagent for demyelinating disease. Adv. Multiple Sclerosis Exp. Demyelinat. Dis. 2008, 318:213-239.
196. Watanabe M., Toyama Y., Nishiyama A. Differentiation of proliferated NG2-positive glial progenitor cells in a remyelinating lesion. J. Neurosci. Res. 2002, 69:826-836.
197. Webb A.A., Ngan S., Fowler J.D. Spinal cord injury I: A synopsis of the basic science. Can. Vet. J. 2010, 51:485-492.
198. Weiner H.L. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?. Ann. Neurol. 2009, 65:239-248.
199. Whitaker C.M., Beaumont E., Wells M.J., Magnuson D.S.K., Hetman M., Onifer S.M. Rolipram attenuates acute oligodendrocyte death in the adult rat ventrolateral funiculus following contusive cervical spinal cord injury. Neurosci. Lett. 2008, 438:200-204.
200. Woerly S., Doan V., Evans-Martin F., Paramore C.G., Peduzzi J.D. Spinal cord reconstruction using NeuroGel (TM) implants and functional recovery after chronic injury. J. Neurosci. Res. 2001, 66:1187-1197.
201. Woerly S., Doan V., Sosa N., de Vellis J., Espinosa A. Reconstruction of the transected cat spinal cord following NeuroGel (TM) implantation: axonal tracing, immunohistochemical and ultrastructural studies. Int. J. Dev. Neurosci. 2001, 19:63-83.
202. Woerly S., Doan V.D., Sosa N., de Vellis J., Espinosa-Jeffrey A. Prevention of gliotic scar formation by NeuroGel (TM) allows partial endogenous repair of transected cat spinal cord. J. Neurosci. Res. 2004, 75:262-272.
203. Woerly S., Petrov P., Sykova E., Roitbak T., Simonova Z., Harvey A.R. Neural tissue formation within porous hydrogels implanted in brain and spinal cord lesions: Ultrastructural, immunohistochemical, and diffusion studies. Tissue Eng. 1999, 5:467-488.
204. Woerly S., Pinet E., De Robertis L., Bousmina M., Laroche G., Roitback T., Vargova L., Sykova E. Heterogeneous PHPMA hydrogels for tissue repair and axonal regeneration in the injured spinal cord. J. Biomater. Sci. Polym. Ed. 1998, 9:681-711.
205. Woerly S., Pinet E., de Robertis L., Van Diep D., Bousmina M. Spinal cord repair with PHPMA hydrogel containing RGD peptides (NeuroGel (TM)). Biomaterials 2001, 22:1095-1111.
206. Wright K.T., El Masri W., Osman A., Chowdhury J., Johnson W.E. Concise review: Bone marrow for the treatment of spinal cord injury: mechanisms and clinical applications. Stem Cells 2011, 29:169-178.
207. Wu Y., Hou J., Collier L., Pan J., Hou L., Qin W., Bauman W.A., Cardozo C.P. The administration of high-dose methylprednisolone for 24 h reduced muscle size and increased atrophy-related gene expression in spinal cord-injured rats. Spinal Cord 2011, 49:867-873.
208. Xu J., Chen S., Chen H., Xiao Q., Hsu C.Y., Michael D., Bao J. STAT5 mediates antiapoptotic effects of methylprednisolone on oligodendrocytes. J. Neurosci. 2009, 29:2022-2026.
209. Yan H.L., Wood P.M. NT-3 weakly stimulates proliferation of adult rat O1(-)O4(+) oligodendrocyte-lineage cells and increases oligodendrocyte myelination in vitro. J. Neurosci. Res. 2000, 62:329-335.
210. Yeo J.E., Kim J.H., Kang S.K. Selenium attenuates ROS-mediated apoptotic cell death of injured spinal cord through prevention of mitochondria dysfunction; in vitro and in vivo study. Cell. Physiol. Biochem. 2008, 21:225-238.
211. Yu L.M.Y., Kazazian K., Shoichet M.S. Peptide surface modification of methacrylamide chitosan for neural tissue engineering applications. J. Biomed. Mater. Res. Part A 2007, 82A:243-255.
212. Yune T.Y., Lee J.Y., Jung G.Y., Kim S.J., Jiang M.H., Kim Y.C., Oh Y.J., Markelonis G.J., Oh T.H. Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury. J. Neurosci. 2007, 27:7751-7761.
213. Zahir T., Nomura H., Guo X.D., Kim H., Tator C., Morshead C., Shoichet M. Bioengineering neural stem/progenitor cell-coated tubes for spinal cord injury repair. Cell Transplant 2008, 17:245-254.
214. Zai L.J., Wrathall J.R. Cell proliferation and replacement following contusive spinal cord injury. Glia 2005, 50:247-257.
215. Zang D.W., Cheema S.S. Leukemia inhibitory factor promotes recovery of locomotor function following spinal cord injury in the mouse. J. Neurotrauma 2003, 20:1215-1222.
216. Zawadzka M., Rivers L.E., Fancy S.P.J., Zhao C., Tripathi R., Jamen F., Young K., Goncharevich A., Pohl H., Rizzi M., Rowitch D.H., Kessaris N., Suter U., Richardson W.D., Franklin R.J.M. CNS-resident glial progenitor/stem cells produce schwann cells as well as oligodendrocytes during repair of CNS demyelination. Cell Stem Cell. 2010, 6:578-590.
217. Zhang J., Kramer E.G., Asp L., Dutta D.J., Navrazhina K., Pham T., Mariani J.N., Argaw A.T., Melendez-Vasquez C.V., John G.R. Promoting myelin repair and return of function in multiple sclerosis. FEBS Lett. 2011.
218. Zheng L., Cui H.F. Use of chitosan conduit combined with bone marrow mesenchymal stem cells for promoting peripheral nerve regeneration. J. Mater. Sci. Mater. Med. 2010, 21:1713-1720.
219. Zimmermann H., Ehrhart F., Zimmermann D., Muller K., Katsen-Globa A., Behringer M., Feilen P.J., Gessner P., Zimmermann G., Shirley S.G., Weber M.M., Metze J., Zimmermann U. Hydrogel-based encapsulation of biological, functional tissue: fundamentals, technologies and applications. Appl. Phys. Mater. Sci. Process. 2007, 89:909-922.